Team finds potential drug targets in deadly pediatric brain tumors

April 6, 2014, Dana-Farber Cancer Institute
This is a photo of Keith Ligon, M.D., Ph.D. (left) and Mark Kieran, M.D., Ph.D., Dana-Farber/ Boston Children's Cancer and Blood Disorders Center. Credit: Dana-Farber/ Boston Children's Cancer and Blood Disorders Center

Researchers studying a rare, always fatal brain tumor in children have found several molecular alterations that drive the cancer, according to a new study from scientists at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and McGill University. The findings identify potential new targets for drug treatments.

The new research could help physicians choose targeted agents with a better chance of combating pediatric high-grade astrocytomas, which are extremely difficult to treat with radiation and surgery. The tumors have resisted treatment attempts with an estimated 250 and combinations over the past 30 years, according to the investigators. Their study was published April 6 in Nature Genetics.

The scientists sequenced tumor biopsy samples and identified a number of mutations or errors in the DNA code. They also found epigenetic changes, which alter how genes are expressed. At least two of the new mutations might be susceptible to blocking by existing drugs, said the investigators. Other molecular targets that they uncovered currently lack specific drugs to attack them but provide new opportunities for future drug development.

These results begin to crack open the genetic "black box" of these tumors, which only now are yielding clues to the abnormal molecular changes that drive them.

"For the most malignant tumor in pediatrics, we finally are beginning to gain a handle on the development of this disease, which is critical to devising effective therapies," says Mark Kieran, MD, PhD, a neuro-oncologist and clinical director of the Brain Tumor Center at Dana-Farber/Boston Children's. Kieran and neuropathologist Keith Ligon, MD, PhD, of Dana-Farber/Boston Children's, are co-senior authors along with two researchers from McGill.

The findings are due in part to a project that began more than 10 years ago when clinicians came together to create a collaborative "precision medicine" clinical trial based at Dana-Farber/Boston Children's. This trial was specifically designed to make discoveries that would change the treatment for children with a type of high grade astrocytoma called diffuse intrinsic pontine glioma (DIPG), the most in children. DIPGs develop in the brainstem—the seat of crucial, basic body functions that keep people alive—and are therefore impossible to remove safely with surgery.

Doctors and patients from more than 20 institutions have now joined this study, which requires taking a biopsy from 100 children, analyzing their tumor tissue using pathology and molecular testing, and planning treatment specifically for each patient based on the results. A goal of the study is to determine whether advanced DNA sequencing and other tools that search for abnormalities and biomarkers can be used to guide potential treatments.

"Instead of treating all the patients the same, this trial obtains a biopsy at the time of diagnosis and the treatment is determined by the expression pattern of the tumor," says Kieran.

Findings in the Nature Genetics study include analysis of biopsy samples from the first group of children enrolled in the trial. In all, 40 tumor specimens underwent sequencing; 25 were from patients with DIPG tumors, some of whom were on the trial.

Most of the tumors were found to harbor a mutation called K27M in the H3F3A protein that is a basic building block of the "epigenome." The effects of this mutation are termed epigenetic because they can change the level of gene activity without changing the structure of a gene's DNA. Mutations in H3F3A have recently been detected in a large percentage of pediatric high-grade astrocytomas, but effective drugs for this mutation have not yet been found.

However, the scientists found that H3F3A mutations always occurred with other mutations that could in theory be targeted by existing drugs. One such new mutation, in the gene ACVR1, was found in five of the diffuse intrinsic pontine gliomas. Interestingly, notes Ligon, this was the first time this gene had been involved in cancer, but the mutation has been identified before as the cause of a rare disorder, "stone man syndrome," where the body's tissues gradually turn to bone.

The researchers discovered additional mutations in the FGFR1 and PI3K cell growth signaling pathways. Drugs exist that can block these overactive pathways and are being tested in other cancers. "These alterations in growth factor receptors and in members of the PI3K pathway offer previously unforeseen therapeutic possibilities in a deadly cancer," the authors commented in their study.

The researchers expect to learn more about these and other as the collaborative effort continues to study more samples of the pediatric tumors.

Explore further: Scientists find mutation driving pediatric brain tumors

More information: Related papers in Nature Genetics, April 6 2014:

dx.doi.org/10.1038/ng.2936
dx.doi.org/10.1038/ng.2938
dx.doi.org/10.1038/ng.2925
dx.doi.org/10.1038/ng.2950

Related Stories

Scientists find mutation driving pediatric brain tumors

April 30, 2013
A type of low-grade but sometimes lethal brain tumor in children has been found in many cases to contain an unusual mutation that may help to classify, diagnose and guide the treatment of the tumors, report scientists at ...

New study on pediatric brain stem tumors

December 3, 2013
Children's National researcher, Javad Nazarian, PhD, authored a new study entitled, "Comparative Multidimensional Molecular Analyses of Pediatric Diffuse Intrinsic Pontine Glioma Reveals Distinct Molecular Subtypes." The ...

High long-term survival of most common pediatric brain tumor, less when radiation was used

February 3, 2014
The first comprehensive, large-scale cohort study of the long-term survival of children treated for low-grade gliomas, the most common pediatric brain tumor, finds that almost 90 percent are alive 20 years later and that ...

Genomic testing links 'exceptional' drug response to rare mutations in bladder cancer

March 13, 2014
A patient with advanced bladder cancer in a phase I trial had a complete response for 14 months to a combination of the targeted drugs everolimus and pazopanib, report scientists led by a Dana-Farber Cancer Institute researcher, ...

Major cancer genotyping study logs 5,000th tumor profile

September 12, 2013
More than 5,000 genetic profiles of tumor DNA have been completed in a large research study by scientists at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Boston Children's Hospital designed to speed the ...

Recurrent but rare mutations might underlie cancer growth

February 26, 2014
A potential new gene mutation that might drive lung cancer development and growth has been identified by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard ...

Recommended for you

New software helps detect adaptive genetic mutations

February 20, 2018
Researchers from Brown University have developed a new method for sifting through genomic data in search of genetic variants that have helped populations adapt to their environments. The technique, dubbed SWIF(r), could be ...

15 new genes identified that shape human faces

February 20, 2018
Researchers from KU Leuven (Belgium) and the universities of Pittsburgh, Stanford, and Penn State have identified 15 genes that determine facial features. The findings were published in Nature Genetics.

New algorithm can pinpoint mutations favored by natural selection in large sections of the human genome

February 20, 2018
A team of scientists has developed an algorithm that can accurately pinpoint, in large regions of the human genome, mutations favored by natural selection. The finding provides deeper insight into how evolution works, and ...

Highly mutated protein in skin cancer plays central role in skin cell renewal

February 20, 2018
Approximately once a month, our skin completely renews itself. If this highly coordinated process goes awry, it can lead to a variety of skin diseases, ranging from skin cancer to psoriasis. Cells lining such organs as skin ...

Study of smoking and genetics illuminates complexities of blood pressure

February 15, 2018
Analyzing the genetics and smoking habits of more than half a million people has shed new light on the complexities of controlling blood pressure, according to a study led by researchers at Washington University School of ...

New mutation linked to ovarian cancer can be passed down through dad

February 15, 2018
A newly identified mutation, passed down through the X-chromosome, is linked to earlier onset of ovarian cancer in women and prostate cancer in father and sons. Kunle Odunsi, Kevin H. Eng and colleagues at Roswell Park Comprehensive ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.